Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models

Ida H Hiemstra, PhD, Maarten L Janmaat, PhD, Peter Boross, PhD, Jeroen van den Brakel, Wessel ten Hagen, Sanne van Dooremalen, Sieto Bosgra, PhD, Bart ECG De Goeij, PhD, Grietje Andringa, Laurens Kil, PhD, A Kate Sasser, PhD, Tahamtan Ahmadi, MD PhD, David Satijn, PhD, Esther CW Breij, PhD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140313

Published: 2020

Journal Articles

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-135874

Published: 2020

Journal Articles

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Saad Z Usmani, MD FACP, Hareth Nahi, Maria-Victoria Mateos, MD PhD, Henk M. Lokhorst, MD PhD, Ajai Chari, MD, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, Professor, Lotfi Benboubker, MD PhD, Peter Hellemans, MD, Tara Masterson, Pamela L Clemens, PhD, Tahamtan Ahmadi, MD, Kevin Liu, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1149.

https://doi.org/10.1182/blood.V128.22.1149.1149

Published: 2016

Journal Articles

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

Hervé Avet-Loiseau, Tineke Casneuf, Christopher Chiu, PhD, Jacob P. Laubach, MD, Je-Jung Lee, Philippe Moreau, Torben Plesner, Professor, Hareth Nahi, Nushmia Z Khokhar, Ming Qi, Jordan Schecter, Victoria Carlton, PhD, Xiang Qin, Kevin Liu, Kaida Wu, MD PhD, Sen H. Zhuang, MD, PhD, Tahamtan Ahmadi, MD, A. Kate Sasser, PhD, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 246.

https://doi.org/10.1182/blood.V128.22.246.246

Published: 2016

Journal Articles

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Homer Adams, III, PhD, Frederik Stevenaert, Jakub Krejcik, Koen Van der Borght, Tineke Casneuf, Tina Smets, Jaime Bald, Yann Abraham, Hugo Ceulemans, Greet Vanhoof, Tahamtan Ahmadi, MD, Saad Z Usmani, MD, Torben Plesner, Professor, Sagar Lonial, MD FACP, Berris van Kessel-Welmers, Henk M. Lokhorst, MD PhD, Tuna Mutis, MD PhD, Niels W.C.J. van de Donk, MD PhD, A. Kate Sasser

Blood (2016) 128 (22): 4521.

https://doi.org/10.1182/blood.V128.22.4521.4521

Published: 2016

Journal Articles

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)

Christopher Chiu, PhD, Tineke Casneuf, Amy Axel, Andrew Lysaght, Jaime Bald, Nushmia Z Khokhar, Torben Plesner, Professor, Saad Z Usmani, MD FACP, Hartmut Goldschmidt, MD, Tahamtan Ahmadi, MD, Kenneth Chan, A. Kate Sasser

Blood (2016) 128 (22): 4531.

https://doi.org/10.1182/blood.V128.22.4531.4531

Published: 2016

Journal Articles

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

Torben Plesner, MD, Hendrik-Tobias Arkenau, MD, Henk M. Lokhorst, MDPhD, Peter Gimsing, MD PhD, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MDPhD, Ulrik Lassen, MDPhD, Jacob P. Laubach, MD, Tahamtan Ahmadi, MD PhD, Howard Yeh, MD, Mary E Guckert, MSN, RN, Huaibao Feng, Nikolai Constantin Brun, MDPhD, Steen Lisby, Linda Basse, MDDMSc, Antonio Palumbo, MD, Paul G. Richardson

Blood (2014) 124 (21): 84.

https://doi.org/10.1182/blood.V124.21.84.84

Published: 2014

Journal Articles

An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma

Philippe Moreau, MD, Maria-Victoria Mateos, Joan Bladé, MD PhD, Lotfi Benboubker, MD PhD, Javier de la Rubia, MD PhD, Thierry Facon, MD, Raymond L. Comenzo, MD, Joseph W. Fay, MD, Xiang Qin, MS, Tara Masterson, MS, Jordan Schecter, MD, Tahamtan Ahmadi, MD, Jesus San Miguel, MD PhD

Blood (2014) 124 (21): 176.

https://doi.org/10.1182/blood.V124.21.176.176

Published: 2014

Journal Articles

High Response Rate To Combination Lenalidomide-Rituximab In FcγRIIIa-F Carriers With Indolent Or Mantle Cell Lymphomas Previously Refractory To Rituximab

Elise A. Chong, MD, Tahamtan Ahmadi, MD, PhD, Nicole A. Aqui, MD, Sunita D. Nasta, MD, Jakub Svoboda, MD, Kristy M. Walsh, BS, Amanda Gordon, CRNP, Stephen J. Schuster, MD

Blood (2013) 122 (21): 250.

https://doi.org/10.1182/blood.V122.21.250.250

Published: 2013

Journal Articles

B Cell Lymphoma, Unclassifiable: Survival Advantage for Aggressive Therapy

Erin Cobain, MD, Tahamtan Ahmadi, MD, PhD, Marc Hoffmann, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Jakub Svoboda, MD, Selina Luger, MD, Edward A. Stadtmauer, MD, Sunita D. Nasta, MD

Blood (2011) 118 (21): 2689.

https://doi.org/10.1182/blood.V118.21.2689.2689

Published: 2011

Journal Articles

Phase II Trial of Lenalidomide - Rituximab +/− Dexamethasone in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab

Tahamtan Ahmadi, MD, PhD, Elise A. Chong, BA, Amanda Gordon, CRNP, Nicole A. Aqui, MD, YinYan Xu, Jakub Svoboda, MD, Sunita D. Nasta, MD, Stephen J. Schuster, MD

Blood (2011) 118 (21): 266.

https://doi.org/10.1182/blood.V118.21.266.266

Published: 2011

Journal Articles

A Study of Outcomes of Diffuse Large B Cell Lymphoma in the Elderly

Marc Hoffmann, MD, Tahamtan Ahmadi, MD, PhD, Erin Cobain, MD, Alison Loren, Noelle V Frey, David Porter, MD, Edward A. Stadtmauer, MD, Stephen J. Schuster, MD, Sunita D. Nasta, MD

Blood (2011) 118 (21): 4950.

https://doi.org/10.1182/blood.V118.21.4950.4950

Published: 2011

Journal Articles

Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance

Jennifer McQuade, MD, Tahamtan Ahmadi, MD, PhD, David Porter, Noelle Frey, Alison Wakoff Loren, MD, MS, Steven C. Goldstein, MD, Jakub Svoboda, MD, Edward Stadtmauer, MD, Stephen J. Schuster, MD, Sunita Dwivedy Nasta, MD

Blood (2010) 116 (21): 3570.

https://doi.org/10.1182/blood.V116.21.3570.3570

Published: 2010

Journal Articles

Phase II Trial of Lenalidomide - Dexamethasone - Rituximab in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab.

Tahamtan Ahmadi, MD, PhD, Elise A. Chong, BA, Amanda Gordon, BA, BSN, RN, Nicole A. Aqui, MD, Lisa H. Downs, CRNP, Leah Leinbach, Steven C. Goldstein, MD, Sunita D. Nasta, MD, Stephen Janofsky, Tapan N. Maniar, MD, Jakub Svoboda, MD, Stephen J. Schuster, MD

Blood (2009) 114 (22): 1700.

https://doi.org/10.1182/blood.V114.22.1700.1700

Published: 2009

Journal Articles

Primary Antigen-Specific B Cells: A Novel Approach to Cellular-Based Immunotherapy.

Tahamtan Ahmadi, MD, PhD, Nathalie Weizmann, MS, Yvonne A. Efebera, MD, David H. Sherr, PhD

Blood (2006) 108 (11): 3717.

https://doi.org/10.1182/blood.V108.11.3717.3717

Published: 2006

NARROW

Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma

High Response Rate To Combination Lenalidomide-Rituximab In FcγRIIIa-F Carriers With Indolent Or Mantle Cell Lymphomas Previously Refractory To Rituximab

B Cell Lymphoma, Unclassifiable: Survival Advantage for Aggressive Therapy

Phase II Trial of Lenalidomide - Rituximab +/− Dexamethasone in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab

A Study of Outcomes of Diffuse Large B Cell Lymphoma in the Elderly

Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance

Phase II Trial of Lenalidomide - Dexamethasone - Rituximab in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab.

Primary Antigen-Specific B Cells: A Novel Approach to Cellular-Based Immunotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only